 |
85 Diseases |  |
26 Trials |
|
26 Trials |  |
4615 News |  |
| «12...1920212223242526272829...5758» |
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Eculizumab-Responsive Adult Onset Protein Losing Enteropathy, Caused by Germline CD55-Deficiency and Complicated by Aggressive Angiosarcoma. (Pubmed Central) - Jan 19, 2022
No abstract available
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. (Pubmed Central) - Jan 19, 2022
No abstract available The findings suggest that, although most patients with refractory gMG will achieve clinical response by Week 12 of eculizumab treatment, first responses can be observed with longer-term treatment.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Soliris to Stop Immune-Mediated Death in COVID-19 (SOLID-C19)-A Compassionate-Use Study of Terminal Complement Blockade in Critically Ill Patients with COVID-19-Related Adult Respiratory Distress Syndrome. (Pubmed Central) - Jan 19, 2022
At the time of this study, the mortality rate in mechanically ventilated COVID-19 patients suffering from ARDS receiving the standard of care as their therapeutic regimen was reportedly as high as 97%. This pilot study demonstrates a 50% mortality rate in patients receiving eculizumab therapy.
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Soliris (eculizumab) / AstraZeneca
Retrospective data, Journal: Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of Kidney Transplant Recipients. (Pubmed Central) - Jan 19, 2022
The effect of enhanced induction, defined as treatment with thymoglobulin, rituximab, and/or eculizumab, often in combination with IVIg and glycosorb, immunoadsorption and/or plasmapheresis/apheresis, was analyzed in a multivariable Cox proportional hazards model together with sex, age, cytomegalovirus mismatch (donor+/recipient-) and rejection treatment as co-predictors...CONCLUSIONS Male sex, but not enhanced induction, was found to be a risk factor for BKVAN development after kidney transplantation. BKVAN is associated with an increased risk of graft loss.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca
Prognostic Biomarkers of NMOSD (Grand Ballroom) - Jan 15, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_84;
sNfL may serve as a predictor of poor outcomes following attacks. Clinical NMO attacks are typically associated with new radiographic lesions; however, a strikingly large number of asymptomatic contrast-enhancing events, occur in NMO.
- | Soliris (eculizumab) / AstraZeneca
Journal: Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy. (Pubmed Central) - Jan 13, 2022
Further understanding of the pathophysiology of the disease may identify additional therapeutic targets. Multiinstitutional, collaborative clinical trials are needed to determine the safety and efficacy of these agents going forward.
- | Soliris (eculizumab) / AstraZeneca
Journal: Response to: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. (Pubmed Central) - Jan 11, 2022
Multiinstitutional, collaborative clinical trials are needed to determine the safety and efficacy of these agents going forward. No abstract available
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Additional eculizumab dose and tacrolimus discontinuation for treatment of COVID-19 in a kidney transplant recipient with aHUS. (Pubmed Central) - Jan 11, 2022
No abstract available No abstract available
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. (Pubmed Central) - Jan 11, 2022
Treatment of catastrophic APS involves triple therapy (anticoagulation, intravenous corticosteroid pulse therapy, and plasma exchange) and may include intravenous immunoglobulin for children and adolescents with this condition. New drugs such as eculizumab and sirolimus seem to be promising drugs for APS.
- | Soliris (eculizumab) / AstraZeneca, Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Journal: The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis. (Pubmed Central) - Jan 11, 2022
Agboola, Nikitin, and Pearson are employed by ICER. Through their affiliated institutions, Tice, Touchette, and Lien received funding from ICER for the work described in this summary.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Eculizumab Use in a Temporarily Dialysis-Dependent Patient With Shiga Toxin-Producing Escherichia Coli Hemolytic Uremic Syndrome With Neurological Complications. (Pubmed Central) - Jan 11, 2022
Following 2 doses of eculizumab, our patient was discharged to an inpatient rehabilitation facility with resolution of her renal injury, seizures, and altered mentation without adverse effects from eculizumab throughout the admission. Based on our case study, it appears that eculizumab may be given during or between hemodialysis without dose adjustment.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Haploidentical Stem Cell Transplant for Paroxysmal Nocturnal Hemoglobinuria-Aplastic Anemia: Case Series (Salt Palace Convention Center Hall A) - Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_1065;
Graft versus host disease (GVHD) prophylaxis consisted of post-transplant cyclophosphamide (50 mg/kg, D+3 – D+4), mycophenolate mofetil (15 mg/kg, D+5 – D+35), and tacrolimus...Paroxysmal nocturnal hemoglobinuria is a rare condition for which allogeneic HSCT is the only curative therapy. Haploidentical transplant proves to be a viable option for pediatric patients with no acceptable unrelated donor, demonstrating excellent outcomes with low transplant-related toxicity.
- Soliris (eculizumab) / AstraZeneca
Neurologic Complications in Pediatric Transplant-Associated Thrombotic Microangiopathy (Salt Palace Convention Center Hall A) - Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_924;
Although a direct relationship between TA-TMA and these symptoms cannot be established in this study design, these findings are consistent with neurologic symptoms described in TMAs unrelated to HCT and suggest altered mental status and seizures are potential manifestations of CNS injury from TA-TMA. Further study of CNS complications of TA-TMA is needed to improve clinical evaluations, shorten the time to intervention and improve long term patient outcomes.
- Soliris (eculizumab) / AstraZeneca
Eculizumab Precision Dosing Algorithm for TA-TMA in Children and Young Adults Undergoing Stem Cell Transplant (Salt Palace Convention Center Hall A) - Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_916;
This study identified an intensified loading protocol to reach at least 80% target attainment. Conclusion The developed models will be incorporated into a clinical decision support tool and precision dosing application to improve outcomes in children and young adults with TA-TMA.
- Soliris (eculizumab) / AstraZeneca
Incidence and Outcomes from Transplant-Associated Thrombotic Microangiopathy in Allogeneic Pediatric Hematopoietic Stem Cell Transplant Recipients before and after the Introduction of Eculizumab: A Single Institution Experience from Oregon Health & Science University (Salt Palace Convention Center Hall A) - Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_901;
Using our diagnostic criteria comparing patients across distinct periods suggests an increase in the incidence of TA-TMA since 2015 at OHSU associated with an increased rate of TA-TMA in non-malignant transplants. Although limited by the sample size, eculizumab appeared to have been used for more ill patients with poor outcomes.
- Soliris (eculizumab) / AstraZeneca
Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy (Salt Palace Convention Center Ballroom I) - Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_805;
There were no measurable differences in complement activation prior to HCT, but SCD patients had elevated markers of endothelial activation compared to non-SCD. TA-TMA was severe in most patients transplanted for SCD.
- | Soliris (eculizumab) / AstraZeneca
Journal: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. (Pubmed Central) - Jan 8, 2022
TA-TMA was severe in most patients transplanted for SCD. No abstract available
- | Soliris (eculizumab) / AstraZeneca
Retrospective data, Journal: Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. (Pubmed Central) - Jan 8, 2022
In patients with severe COVID-19, eculizumab safely improved respiratory dysfunction and decreased the combined endpoint of mortality and discharge with chronic complications. Findings need confirmation in randomised controlled trials.
- | Soliris (eculizumab) / AstraZeneca
Journal: Management of Hyperhemolysis in β-thalassemia With Multiple Immunosuppressives, Including Complement Blockade. (Pubmed Central) - Jan 6, 2022
Hyperhemolysis presents significant challenges in β-thalassemia due to the underlying dysfunctional erythropoiesis and transfusion dependence. Aggressive immunosuppression combined with eculizumab successfully slowed the hemolysis and allowed for the resumption of transfusions.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Thrombotic Microangiopathy (TMA) after Gene Replacemant Therapy (GRT) due to Spinal Muscular Atrophy: Case Summary and Recommendations for Treatment (Pubmed Central) - Jan 6, 2022
Careful follow-up including assessment of proteinuria and blood pressure is recommended since patients may require antihypertensive/nephroprotective treatment to avoid chronic kidney disease in later life. Therefore, GRT in SMA patients should only be performed at centers with neuropediatric and paediatric nephrology expertise.
- ||||| Soliris (eculizumab) / AstraZeneca
DDx TMAs DIC: ⬆️PT/PTT,⬇️fibrinogen TTP: PT/PTT WNL,⬆️fibrinogen ADAMT13<1% (inherited⬇️ or autoAb) AMS AKI rare! Rx = PLEX HUS: AKI Bloody diarrhea Shiga tox ADAMTS13>10% Rx = supportive aHUS: AKI No diarrhea ADAMTS13>10% Complement (Inherited or Ab CFH or I) Rx = Eculizumab (Twitter) - Jan 6, 2022
- || Soliris (eculizumab) / AstraZeneca
Clinical, Review, Journal: Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review. (Pubmed Central) - Jan 1, 2022
Adverse events like VITT, while uncommon, have been described despite vaccination remaining the most essential component in the fight against the COVID-19 pandemic. While it seems logical to consider the use of types of vaccines (eg, mRNA-based administration) in individuals at high risk, treatment should consist of therapeutic anticoagulation mostly with nonheparin products and IVIG.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children. (Pubmed Central) - Jan 1, 2022
PNS manifestations during typical HUS are a rare event and potentially leading to severe disability. A timely clinical assessment is mandatory to set up a prompt therapeutic and rehabilitation program and to obtain a complete clinical and functional recovery.
- | Soliris (eculizumab) / AstraZeneca
Retrospective data, Journal: Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort. (Pubmed Central) - Dec 28, 2021
This finding reinforces the need of eculizumab use for treatment of aHUS kidney transplant patients. Cost optimization analysis and the early access to C5 inhibitors are suggested, especially in low-medium income countries.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Review, Journal: Renal diseases secondary to interferon-β treatment: a multicentre clinico-pathological study and systematic literature review. (Pubmed Central) - Dec 27, 2021
The statistical analysis highlighted that the occurrence of IFN-β-associated TMA was significantly associated with Rebif, with a weekly dose >50 µg and with multiple weekly injections...Patients with TMA lesions received other therapies, including corticosteroids (44%), eculizumab (13%) and plasma exchanges (25%)...IFN-β-associated nephropathy must be sought in the case of HT and/or protU onset during treatment. When TMA and/or FSGS are observed on renal biopsy, early discontinuation of IFN-β is essential.
- |||| cemdisiran (ALN-CC5) / Alnylam, Regeneron, Veopoz (pozelimab-bbfg) / Regeneron
Enrollment open, Combination therapy: ACCESS-1: A C5 Inhibitor-controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy (clinicaltrials.gov) - Dec 27, 2021
P3, N=124, Recruiting, Sponsor: Regeneron Pharmaceuticals
When TMA and/or FSGS are observed on renal biopsy, early discontinuation of IFN-β is essential. Not yet recruiting --> Recruiting
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis. (Pubmed Central) - Dec 25, 2021
Our study shows that heterozygous MCP mutations cause aHUS with a risk of first relapse of about 10% per year, resulting in large NNTs for prevention of relapses with eculizumab. More studies are needed to define an optimal treatment schedule for patients with MCP mutations to minimize the risks of the disease and treatment.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Review, Journal: Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis. (Pubmed Central) - Dec 25, 2021
In this review, we have discussed the treatment time, cost effectiveness, long-term efficacy, and tolerability of eculizumab for MG treatment. We have also summarized historical information and have presented perspectives on this new therapeutic modality.
- || Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab IV) / AstraZeneca
Clinical, Review, Journal: Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. (Pubmed Central) - Dec 24, 2021
In 2019, the FDA approved the second-generation C5 inhibitor ravulizumab, a long-lasting agent with a better control of disease manifestations. Herein, we discuss the use of ravulizumab in PNH, its differences with first-generation C5 inhibitors, the research evidence supporting the safety and efficacy of this drug and its impact on costs for health systems and quality of life of PNH patients.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders. (Pubmed Central) - Dec 22, 2021
Herein, we discuss the use of ravulizumab in PNH, its differences with first-generation C5 inhibitors, the research evidence supporting the safety and efficacy of this drug and its impact on costs for health systems and quality of life of PNH patients. No abstract available
- || Review, Journal: Pegcetacoplan: First Approval. (Pubmed Central) - Dec 22, 2021
Pegcetacoplan is the first C3-targeted paroxysmal nocturnal haemoglobinuria (PNH) therapy to be approved (in May 2021) in the USA, where it is indicated for the treatment of adults with PNH, including those switching from C5 inhibitor therapy with eculizumab and ravulizumab...The recommended dosage regimen of pegcetacoplan is 1080 mg twice weekly, administered as a subcutaneous infusion via an infusion pump with a ≥ 20 mL reservoir. This article summarizes the milestones in the development of pegcetacoplan leading to this first approval for the treatment of adults with PNH.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Thrombotic microangiopathy associated with arboviral infection: Report of 3 cases. (Pubmed Central) - Dec 22, 2021
The third patient had TMA not classified as either aHUS or thrombotic thrombocytopenic purpura (TTP); he abandoned the treatment and returned to the service after 2 years for a dialysis emergency. Patients with arboviral infectious disease and changes that suggest TMA should have appropriate support to establish early diagnosis and useful treatment.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Case series: coronavirus disease 2019 infection as a precipitant of atypical hemolytic uremic syndrome: two case reports. (Pubmed Central) - Dec 22, 2021
Patients with arboviral infectious disease and changes that suggest TMA should have appropriate support to establish early diagnosis and useful treatment. To our knowledge, this represents the largest case series of atypical hemolytic uremic syndrome precipitated by coronavirus disease 2019 in adults.
- || Arzerra (ofatumumab) / Novartis, Genmab, Soliris (eculizumab) / AstraZeneca
Retrospective data, Review: Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis. (Pubmed Central) - Dec 21, 2021
A total of 16 studies were included with 403 patients with refractory MG on therapies with rituximab, eculizumab, tacrolimus, and cladribine...Rituximab had a superior safety profile than eculizumab with a lower incidence of adverse events. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021236818, identifier CRD42021236818.
- Soliris (eculizumab) / AstraZeneca
CompLement C5 Antibodies For Decreasing Brain Injury After Aneurysmal Subarachnoid Hemorrhage (CLASH): A Randomized Controlled Phase II Clinical Trial (Room 243-245) - Dec 21, 2021 - Abstract #ISC2022ISC_533;
P2
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021236818, identifier CRD42021236818. Final results will be presented at the conference.
- |||| Soliris (eculizumab) / AstraZeneca
Where did all the iron go? H. Pylori IgG, urea breath test Rx = Abx Autoimmune gastritis Anti-parietal/IF IgG Rx = IV iron Celiac TTG IgA, duodenal bx Rx = Gluten free PNH Flow CD55/59 Rx = eculizumab IRIDA = iron refractory iron deficiency anemia TMPRSS6 mut Rx = IV iron (Twitter) - Dec 21, 2021
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Eculizumab discontinuation in children and adults with atypical haemolytic uremic syndrome: a prospective multicentric study. (Pubmed Central) - Dec 16, 2021
P4
It improves the management and quality of life of a sizeable proportion of aHUS patients while reducing the cost of treatment. Trail registration number: NCT02574403.
- || Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab IV) / AstraZeneca
Clinical, Journal: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. (Pubmed Central) - Dec 16, 2021
P3
Treatment with ravulizumab provided immediate and complete C5 inhibition, resulting in rapid clinical and laboratory improvements and complete TMA response through 183 days in patients with aHUS triggered by pregnancy. The safety profile observed in this subset of patients analysed is consistent with the 311 study investigating ravulizumab in patients with aHUS naïve to complement treatment.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. (Pubmed Central) - Dec 16, 2021
P3
In both patients, treatment with eculizumab over two months efficiently treated TMA without recurrence and with both patients remaining responsive months after TMA onset. Taken together, we describe two cases of TMA in MM patients on carfilzomib-combination treatment, showing similar courses of this severe adverse reaction, with good responses to two months of eculizumab treatment.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report. (Pubmed Central) - Dec 16, 2021
Due to the similar features of TMA and SLE, clinical suspicion of aHUS in patients with lupus nephritis is important for early diagnosis and prompt management. Timely administration of eculizumab should be considered as a treatment option for aHUS in lupus nephritis patients to yield optimal therapeutic outcomes.
- | Soliris (eculizumab) / AstraZeneca
Enrollment closed: Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients (clinicaltrials.gov) - Dec 14, 2021
P2, N=23, Active, not recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Timely administration of eculizumab should be considered as a treatment option for aHUS in lupus nephritis patients to yield optimal therapeutic outcomes. Recruiting --> Active, not recruiting
- || Soliris (eculizumab) / AstraZeneca
Review, Journal: Native and transplant kidney histopathological manifestations in association with COVID-19 infection: A systematic review. (Pubmed Central) - Dec 7, 2021
Recruiting --> Active, not recruiting This report has clinical relevance as certain renal pathologies have specific management, with the implication that kidney biopsy in the setting of renal disease and COVID-19 should be an early consideration, dependent upon the clinical presentation.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy. (Pubmed Central) - Dec 5, 2021
Early diagnosis and initiation of treatment may improve response. Eculizumab withdrawal can be contemplated in patients who achieve laboratory and clinical resolution of TA-TMA.
- ||| pelecopan (BCX9930) / BioCryst
Enrollment open, Monotherapy: REDEEM-1: BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (clinicaltrials.gov) - Dec 3, 2021
P2, N=81, Recruiting, Sponsor: BioCryst Pharmaceuticals
Eculizumab withdrawal can be contemplated in patients who achieve laboratory and clinical resolution of TA-TMA. Not yet recruiting --> Recruiting
- Soliris (eculizumab) / AstraZeneca
Eculizumab Medication Use Evaluation Across a Five Hospital-health System ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_4405;
- Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab IV) / AstraZeneca
Evaluation of Eculizumab and Ravulizumab Use Within a Large Health System ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_2823;
- Soliris (eculizumab) / AstraZeneca
Drug Use Evaluation of Eculizumab in Pediatric Patients Less Than 12 Years Old ([VIRTUAL]) - Dec 2, 2021 - Abstract #ASHP2021ASHP_183;
- | Soliris (eculizumab) / AstraZeneca
Journal, HEOR: Cost-Utility Analysis of Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria from the Perspective of the Brazilian Public Health System. (Pubmed Central) - Dec 2, 2021
The gain in effectiveness with the use of eculizumab was modest, associated with an unjustifiable incremental cost. Therefore, eculizumab is not a cost-effective drug compared with the current standard of care in the treatment of paroxysmal nocturnal hemoglobinuria from the Brazilian Unified Health System perspective.
- || Soliris (eculizumab) / AstraZeneca
Clinical, Journal: First Report in the Literature of Biopsy-Proven Noncollapsing Focal Segmental Glomerulosclerosis Relapse in a Second Renal Transplant Presenting With Thrombotic Microangiopathy: A Case Report. (Pubmed Central) - Dec 2, 2021
Partial responses to treatments with plasma exchange, eculizumab, and rituximab were obtained, but the allograft was lost after 26 months. This case is the first report of concomitant FSGS and TMA in a renal transplant recipient.
- | Soliris (eculizumab) / AstraZeneca
Journal: Eculizumab in the treatment of neuromyelitis optica spectrum disorder. (Pubmed Central) - Dec 1, 2021
Eculizumab, a humanized monoclonal antibody against the terminal complement component 5, was shown to significantly reduce the risk of NMOSD relapse in a Phase III placebo-controlled trial. Based on this, eculizumab (Soliris) was the first drug to be formally approved for the treatment of anti-AQP4-antibody positive NMOSD in 2019.